Cellebrite DI Balance Sheet Health
Financial Health criteria checks 6/6
Cellebrite DI has a total shareholder equity of $298.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $629.2M and $330.9M respectively. Cellebrite DI's EBIT is $56.2M making its interest coverage ratio 0.2. It has cash and short-term investments of $370.8M.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | 0.2x |
Cash | US$370.76m |
Equity | US$298.32m |
Total liabilities | US$330.93m |
Total assets | US$629.25m |
Recent financial health updates
No updates
Recent updates
Cellebrite: There Are Potential Risks That Could Damper Growth
Nov 08Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?
Oct 30There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased
Sep 10Cellebrite: Rating Downgrade As Valuation Has Caught Up
Aug 27Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up
Aug 17Why We're Not Concerned About Cellebrite DI Ltd.'s (NASDAQ:CLBT) Share Price
Jun 25Is Cellebrite DI Ltd. (NASDAQ:CLBT) Potentially Undervalued?
May 21Cellebrite: Big Fish In A Small Pond
Apr 29Cellebrite DI Ltd.'s (NASDAQ:CLBT) P/S Is Still On The Mark Following 28% Share Price Bounce
Mar 14Cellebrite DI Ltd. (NASDAQ:CLBT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$13.17
Feb 18There's Reason For Concern Over Cellebrite DI Ltd.'s (NASDAQ:CLBT) Price
Jan 28Financial Position Analysis
Short Term Liabilities: CLBT's short term assets ($501.5M) exceed its short term liabilities ($272.9M).
Long Term Liabilities: CLBT's short term assets ($501.5M) exceed its long term liabilities ($58.0M).
Debt to Equity History and Analysis
Debt Level: CLBT is debt free.
Reducing Debt: CLBT has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CLBT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CLBT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.3% per year.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/02 07:04 |
End of Day Share Price | 2025/01/02 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cellebrite DI Ltd. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Tal Liani | BofA Global Research |
Tomer Zilberman | BofA Global Research |
Tyler Radke | Citigroup Inc |